LUXA Biotechnology

Luxa Biotechnology is a clinical stage company advancing an adult RPE stem cell for the treatment of dry AMD. The first dose cohort of our Phase 1/2a clinical have substantial visual gains without cell product-related adverse events.  Luxa collaborations include the Neural Stem Cell Insititute, University of Michigan Kellogg Eye Center, Stanford University Byers Eye Center, Retina-Vitreous Associates Medical Group (LA Retina), Cedars-Sinai Biomanufacturing Center, and the National Institue of Health National Eye Institue. Luxais committed to advancing safe best-in-class vision improvement for AMD patient benefit.